Table 3: Monoclonal Antibodies Dose and LDL-C Reduction.

Monoclonal Antibodies	Reduction of LDL-C from Baseline
Alirocumab
150 mg every two weeks 300 mg every four weeks	66–72 % 43–48 %
Evolocumab
140 mg every two weeks 420 mg every four weeks	51–76 % 48–71 %
Bococizumab
150 mg every two weeks 300 mg every four weeks	33 % (0.5 mg/kg) – 85 % (18 mg/kg) Mean reduction 53 mg/dL Mean reduction 45 mg/dL

low-density lipoprotein cholesterol